Thyrogen: Uses, Dosage & Side Effects

What Is Thyrogen and What Is It Used For?

Thyrogen contains the active substance thyrotropin alfa, a recombinant form of human thyroid-stimulating hormone (TSH) produced using recombinant DNA technology in genetically modified Chinese hamster ovary (CHO) cells. TSH is a glycoprotein hormone naturally produced by the anterior pituitary gland that plays a central role in regulating thyroid function. It consists of two non-covalently linked subunits: an alpha subunit shared with other glycoprotein hormones (such as luteinizing hormone and follicle-stimulating hormone) and a unique beta subunit that confers TSH-specific biological activity. Thyrotropin alfa is biochemically and functionally identical to the endogenous human TSH produced by the pituitary, and it binds to the same TSH receptors on thyroid tissue and thyroid cancer cells.

In the management of well-differentiated thyroid cancer (the most common form of thyroid cancer, encompassing papillary and follicular types), patients typically undergo near-total or total thyroidectomy (surgical removal of the thyroid gland) followed by radioiodine therapy to ablate (destroy) any remaining thyroid tissue. After initial treatment, long-term follow-up involves periodic testing to detect any recurrence or residual disease. These follow-up tests rely on elevated TSH levels to stimulate any remaining thyroid cells (normal or cancerous) to take up radioiodine and produce thyroglobulin (Tg), a protein marker used to detect the presence of thyroid tissue.

Traditionally, elevating TSH levels required withdrawing thyroid hormone replacement therapy (levothyroxine) for several weeks, a process known as thyroid hormone withdrawal (THW). While effective at raising endogenous TSH to the levels needed for diagnostic testing and ablation, THW causes patients to become profoundly hypothyroid, with symptoms including debilitating fatigue, weight gain, constipation, cold intolerance, cognitive impairment, depression, myxoedema, and significantly reduced quality of life. Many patients report that the hypothyroid period is one of the most difficult aspects of their thyroid cancer treatment, and the functional impairment can last for weeks even after levothyroxine is resumed.

Thyrogen was developed to eliminate the need for thyroid hormone withdrawal. By providing an exogenous source of TSH through intramuscular injection, Thyrogen stimulates TSH-dependent thyroid functions – including radioiodine uptake, thyroglobulin synthesis and secretion, and iodine organification – without requiring patients to discontinue their thyroid hormone therapy. This means patients can undergo the necessary diagnostic tests or ablation treatment while maintaining a euthyroid (normal thyroid hormone) state, avoiding the symptoms and morbidity of hypothyroidism.

Thyrogen is approved for two primary clinical indications in adult patients with well-differentiated thyroid cancer who have undergone near-total or total thyroidectomy:

• Diagnostic use: As a stimulation test for serum thyroglobulin (Tg) testing, with or without radioiodine whole-body scintigraphy, to detect thyroid remnants and well-differentiated thyroid cancer. Thyrogen-stimulated Tg testing has been shown to have high sensitivity for detecting recurrent or persistent disease, particularly when combined with neck ultrasonography.
• Remnant ablation: For pre-therapeutic stimulation of radioiodine uptake for the ablation of post-surgical thyroid tissue remnants in patients who do not have evidence of distant metastatic thyroid cancer. Clinical studies have demonstrated comparable ablation success rates between Thyrogen-assisted ablation and thyroid hormone withdrawal-based ablation.

The efficacy of Thyrogen for diagnostic purposes was established in pivotal clinical trials comparing Thyrogen-stimulated Tg testing and radioiodine scanning with the same tests performed after thyroid hormone withdrawal. These studies demonstrated that Thyrogen-stimulated Tg testing, particularly when combined with diagnostic radioiodine whole-body scanning, has comparable sensitivity to withdrawal-based testing for detecting residual or recurrent thyroid cancer. The European and American Thyroid Association guidelines now recommend Thyrogen-stimulated testing as an acceptable alternative to thyroid hormone withdrawal for most follow-up scenarios, with thyroid hormone withdrawal reserved for specific clinical situations where maximum sensitivity is required.

For remnant ablation, randomised controlled trials, including the landmark HiLo study and the ESTIMABL1 trial, have demonstrated that Thyrogen-assisted radioiodine ablation achieves ablation success rates comparable to those achieved with thyroid hormone withdrawal, across both low-dose (1.1 GBq / 30 mCi) and high-dose (3.7 GBq / 100 mCi) radioiodine protocols. These findings have led to Thyrogen being widely adopted as the standard preparation method for remnant ablation in low-to-intermediate risk thyroid cancer patients in many countries.

What Should You Know Before Taking Thyrogen?

Contraindications

The primary contraindication to Thyrogen use is hypersensitivity (allergy) to bovine or human thyroid-stimulating hormone or to any of the other ingredients in the formulation. Thyrotropin alfa is a recombinant human protein, but cross-reactivity with bovine TSH is possible, and patients with a known allergy to bovine TSH should not receive Thyrogen. If you have experienced a previous allergic reaction to Thyrogen or any TSH preparation, you must not receive it again.

Thyrogen is also contraindicated during pregnancy because it is used in conjunction with radioactive iodine for diagnostic scanning or remnant ablation. Radioactive iodine is known to cross the placenta and can damage the foetal thyroid, leading to irreversible congenital hypothyroidism. Even when Thyrogen is used solely for Tg testing without radioiodine, the concurrent use of Thyrogen in pregnancy has not been studied, and the potential risk of TSH-stimulated tumour growth during pregnancy represents an additional concern.

Warnings and Precautions

Before receiving Thyrogen, discuss the following important considerations with your healthcare provider:

• Renal impairment: Thyrogen is eliminated in part through the kidneys, and patients with significant renal impairment (including those on dialysis) may have delayed clearance of thyrotropin alfa, resulting in prolonged elevation of serum TSH levels. This can lead to prolonged stimulation of any residual thyroid tissue and may increase the risk of adverse effects, including headache, nausea, and vomiting. In patients with end-stage renal disease on dialysis, the elimination half-life of TSH is substantially prolonged. The physician should carefully consider the need for Thyrogen in these patients and may need to adjust the radioiodine activity accordingly.
• Metastatic disease: In patients with known distant metastases (particularly in the brain, spinal cord, or structures near the airway), the TSH stimulation caused by Thyrogen can provoke local tumour expansion, oedema, or haemorrhage. Cases of hemiparesis (weakness on one side of the body), acute respiratory distress, and sudden loss of vision have been reported in patients with CNS or orbital metastases following Thyrogen administration. Pre-treatment with glucocorticoids (corticosteroids) should be considered in such patients to reduce the risk of acute complications.
• Hyperthyroidism risk: In patients with significant residual thyroid tissue or functioning metastases, Thyrogen-stimulated iodine uptake and thyroid hormone synthesis may occasionally lead to transient hyperthyroidism. Symptoms can include palpitations, tremor, heat intolerance, and anxiety. This is generally self-limiting but should be monitored.
• Anti-thyroglobulin antibodies: The presence of anti-thyroglobulin antibodies (TgAb) in a patient's serum can interfere with Tg measurements, potentially causing falsely low or undetectable Tg results. This is a limitation of Tg-based surveillance regardless of whether Thyrogen or thyroid hormone withdrawal is used for TSH stimulation. Your doctor will interpret Tg results in the context of your TgAb status.

Pregnancy and Breastfeeding

There are no adequate data on the use of thyrotropin alfa in pregnant women, and animal studies are insufficient to fully assess reproductive toxicity. Given that Thyrogen is almost exclusively used in combination with radioactive iodine – which is known to be teratogenic and is absolutely contraindicated in pregnancy – Thyrogen combined with radioiodine must not be administered to pregnant women under any circumstances.

It is not known whether thyrotropin alfa is excreted in human breast milk. A risk to the breastfed infant cannot be excluded. Breastfeeding should be discontinued before Thyrogen and radioiodine treatment and should not be resumed, as radioiodine is excreted in breast milk and poses a radiation risk to the nursing infant. If Thyrogen is used for Tg testing only (without radioiodine), the decision to breastfeed should be made in consultation with your doctor.

Children and Adolescents

There is limited experience with the use of Thyrogen in children and adolescents. Differentiated thyroid cancer in the paediatric population is relatively rare, and formal clinical trials of Thyrogen in patients under 18 years of age have not been completed. Thyrogen should only be used in children and adolescents in exceptional cases and under the close supervision of an experienced paediatric endocrinologist or oncologist who can weigh the benefits against the potential risks for each individual patient.

Driving and Operating Machinery

Thyrogen may cause dizziness, headache, and fatigue, which could affect the ability to drive or operate machinery. If you experience any of these symptoms after receiving Thyrogen, you should refrain from driving or operating heavy machinery until the symptoms have resolved. The effects are generally transient and resolve within a few days of administration.

How Does Thyrogen Interact with Other Drugs?

Thyrogen (thyrotropin alfa) is a recombinant glycoprotein hormone that is metabolised through general protein catabolic pathways rather than through hepatic cytochrome P450 (CYP) enzyme-mediated metabolism. As such, pharmacokinetic drug-drug interactions of the type commonly seen with small-molecule drugs are not expected with Thyrogen. No formal drug interaction studies have been conducted, and clinical experience has not revealed any significant interactions with commonly used medications.

While Thyrogen itself does not interact with other drugs, it is important to consider the clinical context in which Thyrogen is used. When Thyrogen is administered for radioiodine diagnostic scanning or remnant ablation, the physician must consider the interactions and precautions associated with radioactive iodine. Specifically, the radioiodine activity administered may need to be adjusted based on the patient's clinical situation, including residual thyroid tissue volume, renal function, and other factors that affect radioiodine pharmacokinetics.

Additionally, patients should be aware that certain medications and substances can interfere with radioiodine uptake, potentially reducing the effectiveness of diagnostic scanning or remnant ablation. These include:

Patients should inform their healthcare provider about all medications, supplements (including iodine-containing vitamins), and recent medical procedures (including CT scans with iodinated contrast) before undergoing Thyrogen-assisted radioiodine procedures. A low-iodine diet may be recommended in the days before radioiodine administration to optimise radioiodine uptake.

What Is the Correct Dosage of Thyrogen?

Thyrogen should always be administered by or under the supervision of a healthcare professional experienced in the management of thyroid cancer. The medication is supplied as a lyophilised (freeze-dried) powder that must be reconstituted before intramuscular injection. The dosing protocol is the same for both diagnostic and ablation indications.

Standard Dosing Protocol

The reconstituted solution should be clear and colourless. Do not use the solution if it appears cloudy, discoloured, or contains particulate matter. After reconstitution, the solution should ideally be injected within 3 hours. However, if necessary, the reconstituted solution can be stored for up to 24 hours at 2–8 °C (refrigerated), provided it is protected from light and aseptic conditions are maintained. When stored refrigerated, allow the solution to reach room temperature before injection.

Diagnostic Protocol

When Thyrogen is used for serum Tg testing alone (without radioiodine scintigraphy), the same two-injection protocol is followed, and the Tg blood sample is drawn 72 hours after the second Thyrogen injection. A Tg level that is undetectable or very low under Thyrogen stimulation, in the absence of interfering anti-thyroglobulin antibodies, is highly reassuring and suggests the absence of significant residual or recurrent disease.

Ablation Protocol

The radioiodine activity to be used for Thyrogen-assisted ablation is at the discretion of the nuclear medicine physician and depends on the patient's risk stratification, residual thyroid tissue volume, and institutional protocols. Clinical trials have demonstrated comparable ablation success rates with both low-dose (1.1 GBq / 30 mCi) and high-dose (3.7 GBq / 100 mCi) radioiodine when combined with Thyrogen stimulation.

Overdose

If too much Thyrogen is administered, symptoms of overdose may include nausea, weakness, dizziness, headache, vomiting, and hot flushes. In the event of overdose, treatment is supportive: rehydration should be ensured, and antiemetic medications may be administered to control nausea and vomiting. Given the relatively short elimination half-life of thyrotropin alfa (approximately 25 hours), symptoms of overdose are expected to be self-limiting. However, if the overdose occurs in the context of radioiodine administration, the potential consequences of excessive radioiodine exposure should also be considered, and appropriate radiation safety measures should be taken.

What Are the Side Effects of Thyrogen?

Like all medicines, Thyrogen can cause side effects, although not everyone who receives it will experience them. The side effects observed during clinical trials and post-marketing surveillance are categorised below by their frequency of occurrence. It is important to note that many patients receiving Thyrogen also receive radioactive iodine, and some reported adverse events may be attributable to the radioiodine rather than to Thyrogen itself.

The safety profile of Thyrogen has been well characterised through clinical trials involving over 1,000 patients and extensive post-marketing experience spanning more than two decades. Overall, Thyrogen is well tolerated, with most adverse effects being mild to moderate in severity and transient in nature. The frequency categories below are based on the following convention: very common (affects more than 1 in 10), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), and not known (frequency cannot be estimated from available data).

Nausea is the most frequently reported side effect, occurring in approximately 12% of patients in clinical trials. It is typically mild and self-limiting, resolving within 24–48 hours of administration. Headache and fatigue are also commonly reported and are generally mild. These systemic effects are thought to be related to the transient elevation of TSH and the resulting mild stimulation of any residual thyroid tissue or tissue at other sites.

The most clinically significant adverse events associated with Thyrogen relate to its effects in patients with metastatic disease. TSH stimulation can cause rapid swelling of metastatic thyroid cancer deposits, leading to local oedema, haemorrhage, and compression of adjacent structures. In patients with CNS (brain or spinal cord) metastases, this can manifest as acute hemiparesis (weakness on one side of the body), seizures, or sudden loss of vision. In patients with pulmonary metastases, dyspnoea may occur. In patients with cervical metastases near the airway, acute respiratory compromise has been reported. These serious complications underscore the importance of careful patient selection and the consideration of corticosteroid pre-treatment in patients with known metastatic disease in critical locations.

How Should You Store Thyrogen?

Proper storage of Thyrogen is essential to maintain the quality, safety, and efficacy of the medication. As a biological product (recombinant glycoprotein hormone), thyrotropin alfa is sensitive to temperature extremes, light exposure, and physical stress, all of which can compromise its structural integrity and biological activity.

Follow these storage guidelines carefully:

• Refrigerated storage (before reconstitution): Store Thyrogen vials in the refrigerator at 2–8 °C (36–46 °F). Do not freeze the product. Keep the vials in the original outer carton to protect them from light. The lyophilised (freeze-dried) powder is stable under these conditions until the expiration date printed on the label.
• After reconstitution: Once reconstituted with sterile water for injection, the solution should ideally be injected within 3 hours. If immediate use is not possible, the reconstituted solution may be stored for up to 24 hours at 2–8 °C, provided aseptic conditions were maintained during preparation and the vial is protected from light. Allow the refrigerated reconstituted solution to reach room temperature before injection.
• Do not use if compromised: Visually inspect the reconstituted solution before injection. It should appear as a clear, colourless solution. Do not use Thyrogen if the solution is cloudy, discoloured, or contains visible particles, or if the vial or packaging appears damaged or tampered with.
• Keep out of reach of children: Store Thyrogen in a secure location where children cannot access it.
• Check expiration date: Do not use Thyrogen after the expiration date printed on the vial label and outer carton. The expiration date refers to the last day of that month.
• Disposal: Any unused reconstituted solution and injection materials should be disposed of in accordance with local regulations for pharmaceutical waste. Do not dispose of Thyrogen in household waste or wastewater.

When transporting Thyrogen (for example, to a clinic or hospital for administration), use an insulated container with cold packs to maintain the 2–8 °C storage temperature. Avoid exposing the vials to direct sunlight or excessive heat during transport.

What Does Thyrogen Contain?

Understanding what your medication contains is important, particularly if you have known allergies or sensitivities to specific pharmaceutical ingredients. Below is a detailed breakdown of the composition of Thyrogen.

Active Ingredient

The active substance is thyrotropin alfa, a recombinant human thyroid-stimulating hormone (rhTSH) produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. Each vial contains 0.9 mg of thyrotropin alfa as a lyophilised (freeze-dried) powder. After reconstitution with 1.2 mL of water for injection, each mL of solution contains approximately 0.9 mg of thyrotropin alfa (1.0 mL is withdrawn for injection).

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Thyrogen is supplied as a white to off-white lyophilised (freeze-dried) powder in a glass vial sealed with a rubber stopper and aluminium flip-off cap. After reconstitution with 1.2 mL of water for injection (not included in the pack), the resulting solution is clear and colourless. Thyrogen is available in packs of 1 vial or 2 vials. A full diagnostic or ablation course requires 2 vials (one for each injection). Not all pack sizes may be available in every country.

Thyrogen contains less than 1 mmol (23 mg) of sodium per vial, meaning it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet, although the amount is negligible.

Marketing Authorisation Holder and Manufacturer

Thyrogen is manufactured and marketed by Sanofi (through its specialty care division, formerly Genzyme Corporation). The marketing authorisation holder for the European Union is Sanofi B.V. (Netherlands). In the United States, Thyrogen is marketed by Genzyme Corporation (a Sanofi company). Thyrogen has been approved and available globally since 1998 (FDA approval) and 2000 (EMA approval), and is used in more than 50 countries worldwide for the management of well-differentiated thyroid cancer.